Outcome of HER2 positive breast cancer by PR expression since the introduction of trastuzumab

被引:0
作者
Van Asten, K. [1 ]
Jongen, L. [1 ]
Beuselinck, B. [2 ]
Laenen, A. [3 ]
Wildiers, H. [2 ]
Poppe, A. [4 ]
Floriss, G. [5 ]
Christiaens, M. [6 ]
Neven, P. [4 ]
机构
[1] Katholieke Univ Leuven, Oncol, Leuven, Belgium
[2] UZ Leuven, Gen Med Oncol, Leuven, Belgium
[3] Katholieke Univ Leuven, Interuniv Ctr Biostat & Stat Bioinformat, Leuven, Belgium
[4] UZ Leuven, Gynaecol & Obstet, Leuven, Belgium
[5] UZ Leuven, Imaging & Pathol, Leuven, Belgium
[6] UZ Leuven, Surg, Leuven, Belgium
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P270
引用
收藏
页码:S119 / S119
页数:1
相关论文
共 50 条
  • [31] Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
    Diaz-Gil, Laura
    Braso-Maristany, Fara
    Locatelli, Claudriana
    Centa, Ariana
    Gyorffy, Balasz
    Ocana, Alberto
    Prat, Aleix
    Pandiella, Atanasio
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
  • [32] Long-term trastuzumab treatment in HER2 positive metastatic breast cancer
    Calamac, M.
    Minic, I.
    Tomasevic, Z.
    Oblakovic-Babic, J.
    Serovic, K.
    Djurmez, O.
    Dimitrijevic, M.
    Bozovic-Spasojevic, I.
    BREAST, 2021, 56 : S82 - S83
  • [33] Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies
    Pinto, Ana Catarina
    Ades, Felipe
    de Azambuja, Evandro
    Piccart-Gebhart, Martine
    BREAST, 2013, 22 : S152 - S155
  • [34] Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients
    Hiroyasu Yamshiro
    Hiroji Iwata
    Norikazu Masuda
    Naohito Yamamoto
    Reiki Nishimura
    Shoichiro Ohtani
    Nobuaki Sato
    Masato Takahashi
    Takako Kamio
    Kosuke Yamazaki
    Tsuyoshi Saito
    Makoto Kato
    Tecchuu Lee
    Shinji Ohno
    Katsumasa Kuroi
    Toshimi Takano
    Masahiro Takada
    Shinji Yasuno
    Satoshi Morita
    Masakazu Toi
    International Journal of Clinical Oncology, 2015, 20 : 723 - 724
  • [35] PERSEPHONE: Duration of Trastuzumab with Chemotherapy in women with HER2 positive early breast cancer
    Earl, H. M.
    Cameron, D. A.
    Miles, D.
    Wardley, A. M.
    Ogburn, E. R. M.
    Vallier, A-L
    Loi, S.
    Higgins, H. B.
    Hiller, L.
    Dunn, J. A.
    CANCER RESEARCH, 2012, 72
  • [36] Differential response of HER2 positive breast cancer based on HER2 protein expression level
    Atallah, N. M.
    Toss, M. S.
    Al Saleem, M.
    Green, A. R.
    Mongan, N. P.
    Rakha, E. A.
    JOURNAL OF PATHOLOGY, 2023, 261 : S9 - S9
  • [37] Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
    Laidi, Fatna
    Bouziane, Amal
    Lakhdar, Amina
    Khabouze, Samira
    Rhrab, Brahim
    Zaoui, Fatima
    ONCOTARGETS AND THERAPY, 2014, 7 : 1285 - 1289
  • [38] Changes in the expression of HER2 and other genes in HER2-positive metastatic breast cancer induced by treatment with ado-trastuzumab emtansine and/or pertuzumab/trastuzumab
    Kida, K.
    Lee, J.
    Liu, H.
    Lim, B.
    Murthy, R. K.
    Sahin, A. A.
    Tripathy, D.
    Ueno, N. T.
    CANCER RESEARCH, 2019, 79 (04)
  • [39] Association of basal marker expression with outcome and trastuzumab resistance in HER2-positive breast cancer.
    Chung, Alice P.
    Choi, Michael Phillip
    Bose, Shikha
    Zhang, Xiao
    Varda, Marian
    Cui, Xiaojiang
    Giuliano, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Non linear relationship between HER2 expression and response to trastuzumab in breast cancer
    Valabrega, G.
    Giordano, S.
    Montemurro, F.
    Aglietta, M.
    ANNALS OF ONCOLOGY, 2006, 17 : XI9 - XI9